Total submissions: 6
| Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
|---|---|---|---|---|---|---|---|---|
| Labcorp Genetics |
RCV001093424 | SCV003439655 | pathogenic | not provided | 2025-10-02 | criteria provided, single submitter | clinical testing | This sequence change replaces arginine, which is basic and polar, with glutamine, which is neutral and polar, at codon 334 of the TWNK protein (p.Arg334Gln). This variant is not present in population databases (gnomAD no frequency). This missense change has been observed in individuals with clinical features of autosomal dominant progressive external ophthalmoplegia with mitochondrial DNA deletions (PMID: 12707443, 18973250, 24086434; internal data). It has also been observed to segregate with disease in related individuals. ClinVar contains an entry for this variant (Variation ID: 4623). Invitae Evidence Modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) indicates that this missense variant is expected to disrupt TWNK protein function with a positive predictive value of 80%. Experimental studies are conflicting or provide insufficient evidence to determine the effect of this variant on TWNK function (PMID: 19084593, 20659899, 30496414). This variant disrupts the p.Arg334 amino acid residue in TWNK. Other variant(s) that disrupt this residue have been determined to be pathogenic (PMID: 18575922). This suggests that this residue is clinically significant, and that variants that disrupt this residue are likely to be disease-causing. For these reasons, this variant has been classified as Pathogenic. |
| MGZ Medical Genetics Center | RCV002288465 | SCV002579760 | likely pathogenic | Progressive external ophthalmoplegia with mitochondrial DNA deletions, autosomal dominant 3 | 2021-12-08 | criteria provided, single submitter | clinical testing | |
| Genomics England Pilot Project, |
RCV001542762 | SCV001760246 | pathogenic | Infantile onset spinocerebellar ataxia | criteria provided, single submitter | clinical testing | ||
| Ce |
RCV001093424 | SCV001250392 | pathogenic | not provided | 2016-08-01 | criteria provided, single submitter | clinical testing | |
| Mitochondrial Research Group, |
RCV000508769 | SCV000575924 | pathogenic | Mitochondrial disease | 2017-04-07 | no assertion criteria provided | clinical testing | |
| OMIM | RCV000004886 | SCV000025062 | pathogenic | Progressive external ophthalmoplegia with mitochondrial DNA deletions, digenic | 2003-08-01 | no assertion criteria provided | literature only |